Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCI Annual Report 2014

Apr 25, 2014

52383_rns_2014-04-25_f58771ac-e964-4955-895b-41e1da8a1c7f.pdf

Annual Report

Open in viewer

Opens in your device viewer

公司概況Profile

員工數Employee:205 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣662佰萬元(NTD 662mn) 營業項目Business: 原料藥API(40.96%)

中間體Intermediate(46.82%)

特用化學品 Custom-made chemicals(12.22%)

公司概況 Outline

2
0
1
2
Y
2
0
1
3
Y


E
r
o
p
e
u
4
1
4
%
7
3
6
0
1
%


i
A
m
e
r
c
a
2
2
1
1
%
2
2
8
0
%


i
A
s
a
1
8
1
%
5
2
4
0
0
%


i
T
a
a
n
w
1
8
0
0
%
1
1
9
%
7


l
T
t
o
a
1
0
0
0
0
%
1
0
0
0
0
%

I
S

-

Unit: K NTD

2
0
1
3
2
0
1
4
Q
1
S
l


a
e
s
1
2
9
2
3
4
7
,
,
3
4
4
7
5
7
,
C
O
G
S



(
)
8
9
5
7
5
3
,
(
)
2
4
4
0
2
3
,
f
i
G
P


t
r
o
s
s
r
o
3
9
6
9
8
1
,
1
3
0
5
5
1
,
i
G
P
R



t
a
o
3
0
%
7
3
4
9
%
O
i
E




t
p
e
r
a
n
g
p
e
n
s
e
s
x
(
1
9
1
1
2
2
)
,
(
1
8
6
2
)
5
,
O
i
I




t
e
e
p
r
a
n
g
n
c
o
m
2
0
8
9
5
5
,
8
6
8
9
7
,
i
/
N
O
I
E





t
o
n
p
e
r
a
n
g
n
x
-
(
)
1
2
0
7
9
,
3
0
1
f
i
b
f
N
P
T




t
t
e
r
o
e
o
r
e
a
x
1
9
3
7
8
0
,
7
8
9
9
0
,
I
T



n
c
o
m
e
a
x
(
)
3
3
8
4
2
,
i
f
f
N
P
T




t
t
t
e
r
o
a
e
r
a
x
1
9
9
3
8
5
,

產品組合-Products

Y
2
0
1
1
% Y
2
0
1
2
% Y
2
0
1
3
% A
t
m
o
n
u
D
i-
V
N
a
a
2
%
4.
5
1
V
A
8.
%
1
6
6
P
G
A
8.
3
%
1
1
2
3
8
2
2
6,
6
6,
5
G
P
A
%
1
7.
6
5
G
P
A
%
1
6.
6
1
i-
D
V
N
a
a
%
1
6.
9
2
2
1
8,
7
7
4,
2
5
1
V
A
%
1
3.
7
6
i-
D
V
N
a
a
%
1
5.
9
7
/
S
2
0
3
8
%
8.
3
9
1
0
8,
5
3
5,
7
0
6
P
P
O
N
0.
0
%
1
7
P
P
O
N
8
8
%
7.
V
A
8.
2
3
%
0
3
8,
8
8
1
6,
5
1
M
8
5
%
5.
2
5
P
2
t-
e
n
%
4.
7
8
L
P
F
N
a
%
6.
5
8
8
5,
0
0
6,
8
8
1
P
2
t-
e
n
%
3.
7
3
5-
H
M
T
%
4.
3
3
O
P
P
N
%
6.
5
3
8
4,
4
0
1,
6
6
9
D
B
S
3.
0
8
%
M
8
5
3.
8
9
%
H
M
T
5-
4.
1
%
5
8,
3
3
3
5
5,
7
7
M
1
1
5
%
2.
5
5
S
D
B
%
2.
7
3
P
E
B
N
a
%
3.
9
8
5
1,
4
2
6,
4
8
5
M
7
4
%
2.
3
1
M
1
1
5
%
2.
5
9
N
V
a
a
%
3.
3
4
4
3,
2
1
5,
0
0
2
N
B
E
1.
8
7
%
M
7
4
2.
1
8
%
D
B
S
2.
6
3
%
3
3,
9
5
6,
7
7
3
l
T
t
o
a
%
8
5.
4
0
l
T
t
o
a
%
7
9.
6
2
l
T
t
o
a
%
7
9.
4
2

SCI PHARMTECH, INC.

No. Product $\%$ Sales (NT\$)
1 PGA 18.61% 69,725,187
$\overline{2}$ S20/38 14.33% 53,692,995
3 Di-VaNa 7.68% 28,770,131
$\overline{4}$ Pent-2 5.52% 20,684,828
5 HDFN 5.03% 18,855,149
6 PEB.Na 4.39% 16,454,325
$\overline{7}$ DBS 4.38% 16,399,912
8 5-HMT 4.08% 15,283,200
9 NaVa 4.01% 15,028,868
10 V.A. 3.38% 12,645,146

SCI PHARMTECH, INC.

Divalproex Sodium (Di-Va )

學名藥於2009推出 Generic came out in 2009

Valproic Acid (VA)

20個客戶 20 customers

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease 2個客戶 2 customers

產品介紹Product

Pentobarbital Sodium

鎮定安眠用之原料藥 API used as calmative 4個客戶 4 customers

Anti-inflammatory (Loxoprofen sodium) 2012年銷售 5佰萬 5 mn sales in 2012. 2013年銷售85佰萬 85 mn sales in 2013 日本市場200-300公噸,200美金 /公斤 Japan market:200-300MT at USD 200/kg

S20/38

5-HMT – Ritonavir,Lopinavir

產品介紹Product

  • Antidepressant ( Duloxetine )

2013年底專利到期 Patent expired in the end of 2013

  • 10個客戶 10 customers
  • 中間體為S-MMAA(Intermediate)
  • 近三年營業額約1仟萬 close to 10 mn sales over 3 years

Lorcaserin

Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API

GMP Status(GMP現況 )

A
P
I
C
G
M
P
f
d
i
i
t
c
e
r
e
C
E
P
D
M
F
M
F
D
M
F
(
A
)
T
F
D
(
Q
)
E
D
M
(
S
A
)
U
(
)
J
a
p
a
n
(
C
d
)
a
n
a
a
V
l
i
A
i
d
(
*)
a
p
r
o
c
c
2
0
0
3
2
0
0
4
2
0
0
3
2
0
0
8
2
0
0
8
A
i
l
l
l
o
p
u
r
n
o
2
0
0
4
2
0
0
3
2
0
1
1
P
b
l
r
o
u
c
o
2
0
0
4
2
0
0
4
S
d
i
V
l
t
o
u
m
a
p
r
o
a
e
2
0
0
4
2
0
0
6
D
i
l
S
d
i
(
**
)
a
p
r
o
e
o
m
v
x
u
2
0
0
5
2
0
0
5
2
0
1
0
B
i
l
l
F
t
s
o
p
r
o
o
m
a
r
a
e
u
2
0
0
6
i
S
i
P
b
b
l
d
t
t
e
n
o
a
r
a
o
m
u
2
0
0
9
2
0
1
1
f
i
P
H
d
h
l
d
r
o
p
a
e
n
o
n
e
y
r
o
c
o
r
e
2
0
1
0
2
0
1
2
2
0
1
0
2
0
1
2
2
0
1
2
M
h
l
h
i
d
H
C
l
t
t
e
p
e
n
a
e
y
2
0
1
1
D
l
i
H
d
h
l
i
d
t
o
e
n
e
r
o
c
o
r
e
u
x
y
2
0
1
2
2
0
1
0
/
2
0
1
1
i
i
T
h
l
d
t
o
p
e
n
a
a
c
2
0
1
2
f
S
i
L
d
H
d
t
o
x
o
p
r
o
e
n
o
u
m
y
r
a
e
2
0
1
2
2
0
1
1
A
i
i
i
H
d
h
l
d
t
r
c
a
n
e
y
r
o
c
o
r
e
2
0
1
3
C
l
i
d
i
P
l
i
H
C
l
t
t
n
a
m
y
c
n
a
m
a
e
2
0
1
1
C
l
h
h
i
d
y
c
o
p
o
s
p
a
m
e
2
0
1
2

敬請指教